A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Inclusion Criteria

• Age ≥18 years and body weight ≥42 kg.
• Unresectable or metastatic RCC that has exploited standard of care treatment.
• Karnofsky performance status (KPS) ≥80%.
• Adequate renal, liver, cardiac, and pulmonary organ function.
• Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX130 infusion. Abbreviated

Exclusion Criteria

• Prior treatment with any anti-CD70 targeting agents.
• Prior treatment with any CAR T cells or any other modified T or natural killer (NK) cells.
• History of certain central nervous system (CNS), cardiac or pulmonary conditions.
• Active HIV, hepatitis B virus or hepatitis C virus infection.
• Previous or concurrent malignancy, except treated with curative approach not requiring systemic therapy and in remission for >12 months, or any other localized malignancy with low risk of developing into metastatic disease.
• Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
• Prior solid organ transplantation or bone marrow transplant.
• Pregnant or breastfeeding females.